Zacks: Analysts Expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to Announce -$0.67 Earnings Per Share

Equities research analysts forecast that Protagonist Therapeutics, Inc. (NASDAQ:PTGXGet Rating) will report earnings per share of ($0.67) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Protagonist Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($1.03). Protagonist Therapeutics reported earnings per share of ($0.54) during the same quarter last year, which suggests a negative year-over-year growth rate of 24.1%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($3.43) per share for the current financial year, with EPS estimates ranging from ($4.41) to ($2.78). For the next year, analysts anticipate that the company will post earnings of ($3.93) per share, with EPS estimates ranging from ($4.85) to ($2.88). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGXGet Rating) last announced its quarterly earnings data on Monday, February 28th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.02. The firm had revenue of $8.62 million for the quarter, compared to analysts’ expectations of $7.38 million. Protagonist Therapeutics had a negative return on equity of 40.29% and a negative net margin of 458.94%.

A number of equities research analysts have issued reports on PTGX shares. StockNews.com began coverage on shares of Protagonist Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating for the company. BTIG Research decreased their target price on shares of Protagonist Therapeutics from $55.00 to $45.00 in a research report on Tuesday, April 26th. Finally, Zacks Investment Research raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $57.88.

NASDAQ:PTGX opened at $9.09 on Friday. The stock has a fifty day simple moving average of $22.94 and a 200 day simple moving average of $28.89. Protagonist Therapeutics has a 1-year low of $8.63 and a 1-year high of $50.54.

Several large investors have recently added to or reduced their stakes in the company. CENTRAL TRUST Co acquired a new stake in Protagonist Therapeutics in the 4th quarter valued at $56,000. Lindbrook Capital LLC raised its stake in shares of Protagonist Therapeutics by 444.4% during the 3rd quarter. Lindbrook Capital LLC now owns 2,450 shares of the company’s stock worth $43,000 after purchasing an additional 2,000 shares during the period. Industrial Alliance Investment Management Inc. bought a new stake in shares of Protagonist Therapeutics during the 4th quarter worth $75,000. Royal Bank of Canada raised its stake in shares of Protagonist Therapeutics by 43.7% during the 3rd quarter. Royal Bank of Canada now owns 4,785 shares of the company’s stock worth $85,000 after purchasing an additional 1,455 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Protagonist Therapeutics by 159.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,293 shares of the company’s stock worth $215,000 after purchasing an additional 3,864 shares during the period.

About Protagonist Therapeutics (Get Rating)

Protagonist Therapeutics, Inc, a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.

See Also

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.